AKYA Stock Overview
A life sciences technology company, provides spatial biology solutions for transforming discovery, clinical research, and diagnostics in North America, the Asia-Pacific, Europe, the Middle East, and Africa. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Akoya Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.30 |
| 52 Week High | US$3.42 |
| 52 Week Low | US$0.93 |
| Beta | 1.35 |
| 1 Month Change | 11.11% |
| 3 Month Change | -36.59% |
| 1 Year Change | -32.99% |
| 3 Year Change | -87.25% |
| 5 Year Change | n/a |
| Change since IPO | -95.01% |
Recent News & Updates
Recent updates
Expanding Reagent Offerings And Diagnostics Will Widen Platform Adoption
Expansion of reagent offerings and diagnostics partnerships aim to boost revenue growth and improve margins significantly.Market Cool On Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Pushing Shares 29% Lower
Dec 14
Revenue Downgrade: Here's What Analysts Forecast For Akoya Biosciences, Inc. (NASDAQ:AKYA)
Nov 19Is Akoya Biosciences (NASDAQ:AKYA) Using Too Much Debt?
Nov 12Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Rockets 36% But Many Are Still Ignoring The Company
Oct 08Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target
Aug 09Market Might Still Lack Some Conviction On Akoya Biosciences, Inc. (NASDAQ:AKYA) Even After 31% Share Price Boost
Jun 27Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment?
Jun 24We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now
May 29Investors Continue Waiting On Sidelines For Akoya Biosciences, Inc. (NASDAQ:AKYA)
May 10Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?
Feb 28Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump
Nov 25Shareholder Returns
| AKYA | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 30.0% | -1.6% | -1.4% |
| 1Y | -33.0% | -30.7% | 10.5% |
Return vs Industry: AKYA underperformed the US Life Sciences industry which returned -32% over the past year.
Return vs Market: AKYA underperformed the US Market which returned 9.1% over the past year.
Price Volatility
| AKYA volatility | |
|---|---|
| AKYA Average Weekly Movement | 14.0% |
| Life Sciences Industry Average Movement | 10.5% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: AKYA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AKYA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 205 | Brian McKelligon | www.akoyabio.com |
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions for transforming discovery, clinical research, and diagnostics in North America, the Asia-Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services.
Akoya Biosciences, Inc. Fundamentals Summary
| AKYA fundamental statistics | |
|---|---|
| Market cap | US$64.84m |
| Earnings (TTM) | -US$47.53m |
| Revenue (TTM) | US$79.96m |
Is AKYA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AKYA income statement (TTM) | |
|---|---|
| Revenue | US$79.96m |
| Cost of Revenue | US$30.59m |
| Gross Profit | US$49.37m |
| Other Expenses | US$96.90m |
| Earnings | -US$47.53m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.95 |
| Gross Margin | 61.74% |
| Net Profit Margin | -59.45% |
| Debt/Equity Ratio | -1,298.8% |
How did AKYA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/22 04:22 |
| End of Day Share Price | 2025/05/22 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Akoya Biosciences, Inc. is covered by 8 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Massaro | BTIG |
| Kyle Mikson | Canaccord Genuity |
| Timothy Chiang | Capital One Securities, Inc. |